Search
forLearn
5 / 801 resultslearn Setipiprant
learn Betamethasone Dipropionate
learn Betamethasone
learn Aminexil
Research
5 / 1000+ resultsresearch Rebamipide Induces Hair Regeneration Through EP4-Driven Lipid Metabolism Remodeling
Rebamipide may help regrow hair by activating hair follicle stem cells.
research Eczacılıkta Güncel Araştırmalar
More research is needed to confirm the potential of various treatments, including Helichrysum plicatum, vitamins, bromelain, personalized medications, hydrogels, and bacteriophage therapy.
research Bicalutamide
research Bimatoprost
research 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
Community Join
5 / 1000+ resultscommunity Betamethasone dipropionate 0.05 (sernivo spray)
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
community Beeezula off label (winlevi compounded)
User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community Pyrludimide (KX-826) or Breezula (clascoterone)
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.